Towards Precision Medicine for Bipolar Disorder
Bipolar disorder is a diverse condition characterised by episodic changes in mood with partial or complete recovery of illness between episodes. It is estimated that this condition has a worldwide prevalence of at least 2%. Treatment options for bipolar disorder have increased in the last two decades but lithium has long been established as the first-line treatment.
Although lithium therapy is regarded as the gold-standard treatment for bipolar disorder it can be associated with important long-term side-effects and there is currently no reliable method for accurately predicting which patients will respond well to lithium.
In the last few years several research studies have found that genetic factors may have an influence on the response to lithium in bipolar disorder. This study will be assessing whether genetic and non-genetic factors are potentially useful for predicting response to lithium.
For this study the researchers are looking for people with a diagnosis of bipolar disorder and are being treated with lithium or have received lithium treatment in the past.
If you would like to hear more about this study, please email firstname.lastname@example.org or call 01382 383235/383431.
To check your eligibility for this study please complete the short questionnaire below. If you wish to take part, please ensure that you register with SHARE on completion (even if you have already done so in the past) so that we can contact you.